Partner David Rosen was quoted in a Newsweek article published on May 1, 2014, titled “Be Still, My Bioficial Heart.” The article explained the benefits and challenges of creating a “bioficial heart,” which researchers at the University of Louisville recently announced could be developed using living cells from a potential transplant patient combined with artificial materials to create a fully functional 3-D printed heart. Given that the U.S. Food and Drug Administration (FDA) is many years out from approving lab-built organs for patients, Rosen said, “The potential challenges include demonstrating that the organs will function as predicted, demonstrating the sustainability of these organs once transplanted and obtaining approval to test and market these from [the] FDA.”
People
Related News
February 6, 2026
In the News
Louis Lehot Featured for Insights on Evolution of Dealmaking
Foley & Lardner LLP partner Louis Lehot highlighted the evolution of dealmaking in the Silicon Valley Business Journal article, "The Old Playbook Doesn't Work Anymore."
February 6, 2026
In the News
Gregory Husisian on What U.S.-India Trade Deal Means for Fashion Supply Chains
Foley & Lardner LLP Gregory Husisian discussed the broader geopolitical evolution of the US-India agreement in the Vogue Business article, “What the US-India Trade Deal Could Mean for Fashion’s Supply Chains.”
February 2, 2026
In the News
Aaron Maguregui Outlines AI Regulation and Pharma Challenges in Health Care
Foley & Lardner LLP partner Aaron Maguregui examining the regulatory landscape for AI in the health care industry in the PharmaVoice article, “As artificial intelligence increasingly takes on new patient-facing roles, laws lag behind.”